期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

LC-MS^n测定2-[[(2′-氰基联苯基)-4-基]甲基]氨基-3-硝基苯甲酸乙酯中的不纯物

Determination of Impurities in Ethyl-2-[[2′-cyanobiphenyl-4-yl]-methyl] amino]-3-nitrobenzoate by LC-MS^n
下载PDF
导出
摘要 The impurities in ethyl-2-[[2′-cyanobiphenyl-4-yl] methyl] amino]-3-nitrobenzoate,an intermediate for synthesis of candesartan cilexiti,were detected by LC-MSn. The structural assignment of these impurities was carried out by LC-MSn using electrospray ionization source and an ion trap mass analyzer. The formation of the impurities was discussed. Also the fragmentation pathways of these compounds were studied. The impurities in ethyl-2-[[2′-cyanobiphenyl-4-yl] methyl] amino]-3-nitrobenzoate,an intermediate for synthesis of candesartan cilexiti,were detected by LC-MSn. The structural assignment of these impurities was carried out by LC-MSn using electrospray ionization source and an ion trap mass analyzer. The formation of the impurities was discussed. Also the fragmentation pathways of these compounds were studied.
作者 姚骏骅
机构地区 中山大学测试中心
出处 《分析测试学报》 CAS CSCD 北大核心 2007年第z1期125-126,共2页 Journal of Instrumental Analysis
关键词 LC-MSn Ethyl-2-[[2′-cyanobiphenyl-4-yl] methyl] amino]-3-nitrobenzoate IMPURITIES Fragmentation pathways LC-MSn Ethyl-2-[[2′-cyanobiphenyl-4-yl] methyl] amino]-3-nitrobenzoate Impurities Fragmentation pathways
分类号 O657-55 [理学—分析化学]
  • 相关文献

参考文献3

二级参考文献11

  • 1邢为凡,韩冬梅,陈淑珍,邢亚菲.头孢泊肟酯合成研究Ⅰ．1－碘乙基异丙基碳酸酯的制备[J].中国药科大学学报,1996,27(4):198-201. 被引量：9
  • 2Kobe TN, Kyoto KN, Higashiosaka TK, et al. 1-( Cyclohexyloxycarbonyloxy ) ethyl 2-ethoxy-1- { [ 2'-( 1H-tetrazol-5-yl ) biphenyl-4-yl ] methyl }-lH-benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof[P]. US: 5196444,1993-05-23. (CA 1993,116:128924).
  • 3Manolis A J, Grossman E, Jelakovic B, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension[J]. Clin Ther,2000,22(10) :1186-1203.
  • 4Malmqvist K, Kahan T, Dahl M. Angiotensin I type 1 (AT1) receptor blockade in hypertensive women :benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide[J]. Am J Hypertens, 2000,13 ( 5 ) :504-511.
  • 5Kojima M, Shiojima I, Yamazaki T, et al. Angiotensin I receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediatd cardiomyocyte hypertrophy in vitro[J]. Circulation, 1994,89 (5) : 2204-2211.
  • 6Kubo K, Kohara Y, Imamiya E, et al. Nonpeptide angiotensin Ⅰ receptor antagonists.Synthesis and biological activity of henzimidazolecarhoxylic acids[J].J Med Chem, 1993,36( 15 ) : 2182-2195.
  • 7Nishmura T, Yoshimura Y, Miyake A, et al. Orally active 1-(cyclohexyloxycarbonyloxy)alkyl ester prodrugs of cefotiam[J]. J Antitbiot, 1987,40(1):81-90.
  • 8H. Buter,G. Y. Navis,A. J. J. Woittiez,D. de Zeeuw,P. E. de Jong. Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function[J] 1999,European Journal of Clinical Pharmacology(12):953～958
  • 9K. Fridman,O. K. Andersson,M. Wysocki,P. Friberg,M. Sunzel. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients[J] 1998,European Journal of Clinical Pharmacology(7):497～501
  • 10J. F. W. Hoogkamer,C. H. Kleinbloesem,M. Ouwerkerk,A. H?gemann,A. Nokhodian,W. Kirch,E. Weidekamm. Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function[J] 1998,European Journal of Clinical Pharmacology(4):341～345

共引文献18

分析测试学报
2007年 第z1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部